Glucagon-Like Peptide-1 Receptor Agonists and Suicidality-Two Important Pieces of Data but an Incomplete Puzzle

Timothy S Anderson^{1

2}, Deborah Grady^{3

4}

Affiliations

¹ Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
² Associate Editor, JAMA Internal Medicine.
³ Department of Medicine, University of California, San Francisco.
⁴ Deputy Editor, JAMA Internal Medicine.

Timothy S Anderson et al. JAMA Intern Med. 2024.

. 2024 Nov 1;184(11):1312-1313.

doi: 10.1001/jamainternmed.2024.4320.

Timothy S Anderson^{1

2}, Deborah Grady^{3

4}

¹ Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
² Associate Editor, JAMA Internal Medicine.
³ Department of Medicine, University of California, San Francisco.
⁴ Deputy Editor, JAMA Internal Medicine.

No abstract available

Comment in

GLP-1 Receptor Agonist Use and Risk of Suicide Death.
Ueda P, Söderling J, Wintzell V, Svanström H, Pazzagli L, Eliasson B, Melbye M, Hviid A, Pasternak B. Ueda P, et al. JAMA Intern Med. 2024 Nov 1;184(11):1301-1312. doi: 10.1001/jamainternmed.2024.4369. JAMA Intern Med. 2024. PMID: 39226030 Free PMC article.
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
Wadden TA, Brown GK, Egebjerg C, Frenkel O, Goldman B, Kushner RF, McGowan B, Overvad M, Fink-Jensen A. Wadden TA, et al. JAMA Intern Med. 2024 Nov 1;184(11):1290-1300. doi: 10.1001/jamainternmed.2024.4346. JAMA Intern Med. 2024. PMID: 39226070 Free PMC article. Clinical Trial.